Supernus Pharmaceuticals Revenue and Competitors

Location

$539.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Supernus Pharmaceuticals's total funding is $539.5M.

Employee Data

  • Supernus Pharmaceuticals has 708 Employees.(i)
  • Supernus Pharmaceuticals grew their employee count by 9% last year.

Supernus Pharmaceuticals's People

NameTitleEmail/Phone
1
Sr. VP, Regulatory AffairsReveal Email/Phone
2
Executive Director, Sales Leadership Development & Inside SalesReveal Email/Phone
3
SVP Quality,GMP Operations & IT at Supernus PharmaceuticalsReveal Email/Phone
4
VP and Head Clinical DevelopmentReveal Email/Phone
5
Sr. Executive Assistant to SVP Sales & MarketingReveal Email/Phone
6
VP, BiometricsReveal Email/Phone
7
VP Corporate AccountsReveal Email/Phone
8
VP - ADHD DivisionReveal Email/Phone
9
SVP, Supply ChainReveal Email/Phone
10
Head Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M35-3%N/AN/A
#2
$7.2M36-5%N/AN/A
#3
$10.5M52-9%N/AN/A
#4
$344.1M17129%N/AN/A
#5
$27.5M1376%N/AN/A
#6
$107.3M5349%N/AN/A
#7
$12.9M6428%N/AN/A
#8
$31.6M1571%N/AN/A
#9
$31.4M1567%N/AN/A
#10
$11.5M5730%N/AN/A
Add Company

What Is Supernus Pharmaceuticals?

Headquartered in Rockville, MD, Supernus Pharmaceuticals, Inc. (formerly Shire Laboratories) is a specialty pharmaceuticals company that has a broad portfolio of proven and patented drug delivery technologies. Among its key technologies are ProScreen® and OptiScreen® for lead selection and formulation optimization, Microtrol®, Solutrol® and EnSoTrol®, its oral controlled release technologies, and AvertSM, its reduced abuse potential technology. Supernus will focus on developing differentiated products for targeted specialty therapeutic areas on its own and in partnership with other pharmaceutical companies.

keywords:N/A

$539.5M

Total Funding

708

Number of Employees

N/A

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Supernus Pharmaceuticals News

2022-04-19 - Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered ...

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of...

2022-04-17 - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Expected to ...

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of...

2022-04-17 - Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to Buy at ...

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of...

2021-11-23 - Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$144.7M7134%N/A
#2
$292.7M7210%N/A
#3
$35M724N/AN/A
#4
$35M7579%N/A
#5
$295.3M81313%N/A